
Atty. Dkt. No. 065691-0438



## Amendments to the Specification:

Please amend the specification as follows:

(I) Page 1, lines 4-19: please delete the paragraphs and substitute therefore with following paragraphs:

"The subject of the present invention is a new stable formulation in the form of sustained-release microgranules containing Gingko Biloba Ginkgo biloba extract as well as the process for preparing it.

More precisely, the present invention relates to microgranules in the form of a core containing Gingko Biloba Ginkgo biloba extract with at least one pharmaceutically acceptable excipient, an intermediate layer coating said core, and an outer layer, which enables sustained release of Gingko Biloba Ginkgo biloba from the core.

Gingko Biloba Ginkgo biloba extract contains flavone glycosides (flavonoids), such as quercetin, kaemferol, isorhamnetin and terpenes (heterosides) such as Bilobadide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J."

(II) Page 2 lines 4-22: please delete the paragraphs and substitute therefore with following paragraphs:

"The multiparticulate form of the invention makes it possible to obtain a stable and reproducible sustained release multiparticulate dosage form comprising Gingko Biloba Ginkgo biloba extract, with the advantage of being stable during storage, particularly in accelerated storage conditions, defined in ICH as 40°C for temperature and 75% for relative humidity.

According to the present invention, the sustained release microgranules contain a Gingko Biloba Ginkgo biloba extract, characterized by the release of total flavone glycosides having the following profile of dissolution rates, measured at 37.0°C ± 0.5°C, with a Dissolution Test Apparatus I (Basket method at 100 rpm, 900 mL of purified water, W Detection: 272 nm):"